Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 9/20 | 0.42 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.42 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.41 |
| ▸ | SCD | O00767 | 1/20 | 0.41 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6650001 | 0.90 | TRPV4 (0.45) | TRPV4HIF1ASCDSCD5 | |
| SCHEMBL7201171 | 0.88 | SCD (0.43) | SCDSCD5ALDH1A1KMT2ATDP1 | |
| SCHEMBL6645501 | 0.84 | LMNA (0.47) | TRPV4HIF1AMAPT | |
| SCHEMBL6642965 | 0.79 | SCD (0.41) | TRPV4SCDSCD5ALDH1A1MAPT | |
| SCHEMBL6644600 | 0.78 | SCD (0.42) | TRPV4SCDSCD5ALDH1A1KMT2A | |
| SCHEMBL6649993 | 0.76 | LMNA (0.43) | TRPV4HIF1AMAPT | |
| SCHEMBL6648250 | 0.75 | L3MBTL1 (0.43) | ALDH1A1KMT2ATDP1MAPTRAB9A | |
| SCHEMBL6643832 | 0.73 | NAMPT (0.42) | HIF1AALDH1A1KMT2AMAPTRAB9A | |
| SCHEMBL6687617 | 0.72 | LMNA (0.51) | HIF1AMAPT | |
| SCHEMBL6644189 | 0.72 | AURKA (0.41) | SCDSCD5ALDH1A1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040133008-A1 | Amide compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040133008-A1 | Amide compounds | APOB, APOL1, LDLR | TRPV4 3973/4885CYP2C8 1959/4885CYP2B6 1039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.